InvestmentJul 22, 2026, 07:07 AM
Royalty Pharma acquires cliramitug royalty for up to $425M
AI Summary
Royalty Pharma plc announced the acquisition of a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million. The payment structure includes $125 million upfront, $125 million in Q1 2027, and $175 million tied to clinical and regulatory milestones. Cliramitug is a Phase 3 TTR-fibril-depleting antibody for ATTR-CM, a progressive heart disease, with trial results anticipated in 2028. The ATTR-CM market surpassed $7 billion in 2025, and AstraZeneca forecasts cliramitug peak sales between $3 billion and $5 billion.
Key Highlights
- Royalty Pharma acquired a royalty interest in cliramitug for up to $425 million.
- The deal includes an upfront payment of $125 million to Neurimmune.
- An additional $125 million will be paid in the first quarter of 2027.
- Remaining $175 million is contingent on clinical and regulatory milestones.
- Royalty Pharma will receive a 3% to 4% royalty on worldwide net sales of cliramitug.
- Cliramitug is a Phase 3 drug for ATTR-CM, with results expected in 2028.
- The ATTR-CM market exceeded $7 billion in sales in 2025.
- AstraZeneca projects cliramitug peak sales between $3 billion and $5 billion.
Price Impact
More from RPRX